Announcement • Jun 30
Edan Instruments, Inc. to Report First Half, 2026 Results on Aug 26, 2026 Edan Instruments, Inc. announced that they will report first half, 2026 results on Aug 26, 2026 Buy Or Sell Opportunity • May 11
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 3.1% to CN¥15.23. The fair value is estimated to be CN¥12.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Announcement • Mar 31
Edan Instruments, Inc. to Report Q1, 2026 Results on Apr 24, 2026 Edan Instruments, Inc. announced that they will report Q1, 2026 results on Apr 24, 2026 Reported Earnings • Mar 31
Full year 2025 earnings released: EPS: CN¥0.53 (vs CN¥0.28 in FY 2024) Full year 2025 results: EPS: CN¥0.53 (up from CN¥0.28 in FY 2024). Revenue: CN¥2.00b (up 9.0% from FY 2024). Net income: CN¥305.6m (up 89% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Mar 31
Edan Instruments, Inc., Annual General Meeting, Apr 21, 2026 Edan Instruments, Inc., Annual General Meeting, Apr 21, 2026, at 15:30 China Standard Time. Location: No. 15, Jinhui Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen, Guangdong China Announcement • Mar 30
Edan Instruments, Inc. Launches Edan Nano Ob Assist, An Ai-Enabled Handheld Ultrasound System Edan Instruments, Inc. announced the launch of EDAN Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to essential prenatal screening in low-resource and underserved settings. Unveiled at a launch event in Nairobi on March 23, 2026 attended by healthcare professionals, Ministry of Health representatives, NGOs, and regional partners, EDAN Nano OB Assist introduces a simplified approach to obstetric ultrasound through AI-enabled blind sweep technology, enabling caregivers to obtain key clinical measurements with reduced reliance on advanced training. EDAN Nano OB Assist received CE marking on March 18, 2026, demonstrating compliance with European Union safety and performance requirements. As a new generation of AI-enabled ultrasound technology, this milestone underscores its readiness for clinical use and supports its potential to expand access to essential prenatal screening in underserved regions. Unlike conventional ultrasound systems that require skilled sonographers and complex workflows, EDAN Nano OB Assist is designed to support frontline healthcare providers by automating image analysis and delivering essential insights, including gestational age, fetal presentation, and estimated delivery date, etc. According to the World Health Organization, approximately 178,000 women in Africa die each year from pregnancy and childbirth-related complications, many of which are preventable. However, access to ultrasound — a critical tool in prenatal assessment — remains limited in many regions due to resource constraints and a shortage of trained professionals. During the event, EDAN demonstrated the device in a live, side-by-side comparison with a conventional ultrasound system, highlighting differences in workflow, time efficiency, and ease of use. The demonstration underscored the potential of AI-enabled scanning to support broader adoption of ultrasound in primary and community care settings. EDAN also highlighted its ongoing commitment to healthcare development in Africa through its Kenya office, which supports local partnerships, clinical training, and product implementation across the region. The launch of EDAN Nano OB Assist reflects EDAN's broader focus on developing accessible, clinically meaningful technologies that address real-world healthcare challenges. Buy Or Sell Opportunity • Jan 05
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to CN¥13.79. The fair value is estimated to be CN¥10.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 11%. Announcement • Dec 31
Edan Instruments, Inc. to Report Fiscal Year 2025 Results on Mar 31, 2026 Edan Instruments, Inc. announced that they will report fiscal year 2025 results on Mar 31, 2026 Buy Or Sell Opportunity • Dec 18
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 6.7% to CN¥12.85. The fair value is estimated to be CN¥10.67, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 11%. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥14.01, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 41x in the Medical Equipment industry in China. Total returns to shareholders of 18% over the past three years. Buy Or Sell Opportunity • Oct 28
Now 30% overvalued after recent price rise Over the last 90 days, the stock has risen 7.2% to CN¥13.97. The fair value is estimated to be CN¥10.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 11%. Announcement • Sep 30
Edan Instruments, Inc. to Report Q3, 2025 Results on Oct 28, 2025 Edan Instruments, Inc. announced that they will report Q3, 2025 results on Oct 28, 2025 Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.15 (up from CN¥0.15 in 2Q 2024). Revenue: CN¥493.5m (up 3.1% from 2Q 2024). Net income: CN¥89.4m (up 3.2% from 2Q 2024). Profit margin: 18% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Jul 02
Edan Instruments, Inc. to Report First Half, 2025 Results on Aug 26, 2025 Edan Instruments, Inc. announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • Apr 25
Edan Instruments, Inc. Proposes Final Cash Dividend for 2024 Edan Instruments, Inc. proposed final cash dividend of CNY 2.07000000 per 10 shares (tax included) for 2024. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.066 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.066 in 1Q 2024). Revenue: CN¥420.4m (down 5.2% from 1Q 2024). Net income: CN¥65.1m (up 69% from 1Q 2024). Profit margin: 16% (up from 8.7% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • Apr 24
Edan Instruments, Inc., Annual General Meeting, May 15, 2025 Edan Instruments, Inc., Annual General Meeting, May 15, 2025, at 15:30 China Standard Time. Location: No. 15, Jinhui Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen, Guangdong China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (8.7% net profit margin). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥10.10, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 32x in the Medical Equipment industry in China. Negligible returns to shareholders over past three years. Announcement • Mar 31
Edan Instruments, Inc. to Report Q1, 2025 Results on Apr 24, 2025 Edan Instruments, Inc. announced that they will report Q1, 2025 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥12.89, the stock trades at a trailing P/E ratio of 47.8x. Average trailing P/E is 32x in the Medical Equipment industry in China. Total returns to shareholders of 19% over the past three years. New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (8.7% net profit margin). Announcement • Dec 31
Edan Instruments, Inc. to Report Fiscal Year 2024 Results on Apr 24, 2025 Edan Instruments, Inc. announced that they will report fiscal year 2024 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to CN¥13.98, the stock trades at a trailing P/E ratio of 51.8x. Average trailing P/E is 34x in the Medical Equipment industry in China. Total returns to shareholders of 11% over the past three years. Announcement • Nov 12
Edan Instruments, Inc. Unveils Latest Innovations for Global Healthcare at MEDICA 2024 Edan Instruments, Inc. showcased its latest product innovations at MEDICA 2024 in Germany. The event, held from November 11 to 14, attracted over 83,000 attendees and 5,300 exhibitors, highlighting advancements in healthcare technology. Marking 10 years in the blood gas field, EDAN officially reaching audiences with i500 this year, as one of the world's smallest benchtop analyzers with true zero maintenance, delivering over 30 parameters per test. The new Blood Sampler offers safer sampling with size options, ensuring accuracy by reducing ion interference via calcium-balanced heparin-lithium coating. Expanding in IVD, EDAN introduces the H90 Series hematology analyzer, utilizing 3D fluorescence technology for precise RET, DIFF and NRBC results. In ultrasound, EDAN highlighted the Acclarix AX9, a portable diagnostic ultrasound system featuring the cutting-edge SynSight zone sonography platform, which drew widespread attention for its robust performance as a powerful solution for diverse clinical settings. Alongside the AX9, the Nano Series handheld systems offer compact and user-friendly technology to meet the demand for high-quality, portable imaging. EDAN's F15 Series fetal and maternal monitors are trusted for their reliability and performance. Recognized by renowned institutions worldwide, the F15 continues to evolve based on client feedback, ensuring it meets the demands of modern obstetric care with precision and confidence. The PA4 Pro biofeedback system provides a portable solution for pelvic floor rehabilitation, receiving positive feedback from healthcare professionals. Additionally, the C12 UHD colposcope brings ultra-high-definition imaging with a 4K camera, delivering detailed visualization of lesion morphology and vascular characteristics for gynecological diagnostics. In patient monitoring, EDAN's upcoming iV100 is a versatile solution, functioning seamlessly as a multi-parameter module within the iV series, while also serving as a transport monitor and bedside monitor in one. Designed for use across diverse settings--from ambulances to hospitals--it ensures uninterrupted access to patient data, facilitating seamless, continuous and effective care. This commitment to adaptable, user-friendly design extends to cardiology. The soon-to-be-released SE-1202E 12-channel ECG features a high-resolution screen, and streamlined touch controls for easy cleaning and enhanced usability in cardiac diagnosis, while the new compact SE-310 ECG brings portability and efficiency to primary care. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.051 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.081 (up from CN¥0.051 in 3Q 2023). Revenue: CN¥459.9m (up 6.1% from 3Q 2023). Net income: CN¥46.8m (up 57% from 3Q 2023). Profit margin: 10% (up from 6.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥10.39, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total loss to shareholders of 1.6% over the past three years. Announcement • Sep 30
Edan Instruments, Inc. to Report Q3, 2024 Results on Oct 25, 2024 Edan Instruments, Inc. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥11.35, the stock trades at a trailing P/E ratio of 47.2x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total returns to shareholders of 3.3% over the past three years. Buy Or Sell Opportunity • Sep 19
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 1.9% to CN¥9.05. The fair value is estimated to be CN¥7.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 14%. Announcement • Jun 29
Edan Instruments, Inc. to Report First Half, 2024 Results on Aug 30, 2024 Edan Instruments, Inc. announced that they will report first half, 2024 results on Aug 30, 2024 Declared Dividend • Apr 29
Dividend of CN¥0.21 announced Dividend of CN¥0.21 is the same as last year. Ex-date: 6th May 2024 Payment date: 6th May 2024 Dividend yield will be 2.1%, which is about the same as the industry average. Sustainability & Growth Dividend is not covered by earnings (100% earnings payout ratio). However, it is covered by cash flows (85% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 12% to bring the payout ratio under control, which is more than the 3.0% EPS growth achieved over the last 5 years. New Risk • Apr 26
New major risk - Revenue and earnings growth Earnings have declined by 2.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.8% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (100% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin). Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.066 (vs CN¥0.24 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.066 (down from CN¥0.24 in 1Q 2023). Revenue: CN¥443.6m (down 31% from 1Q 2023). Net income: CN¥38.5m (down 73% from 1Q 2023). Profit margin: 8.7% (down from 22% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Mar 30
Edan Instruments, Inc. to Report Q1, 2024 Results on Apr 26, 2024 Edan Instruments, Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 29
Edan Instruments, Inc., Annual General Meeting, Apr 22, 2024 Edan Instruments, Inc., Annual General Meeting, Apr 22, 2024, at 15:30 China Standard Time. Location: No. 15, Jinhui Road, Jinsha Community, Kengzi Subdistrict, Pingshan District, Shenzhen, Guangdong China Reported Earnings • Mar 29
Full year 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.40 in FY 2022) Full year 2023 results: EPS: CN¥0.38 (down from CN¥0.40 in FY 2022). Revenue: CN¥1.94b (up 11% from FY 2022). Net income: CN¥221.3m (down 5.0% from FY 2022). Profit margin: 11% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to CN¥12.56, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total loss to shareholders of 22% over the past three years. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥7.55, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 24x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past three years. Announcement • Dec 30
Edan Instruments, Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024 Edan Instruments, Inc. announced that they will report fiscal year 2023 results on Mar 29, 2024 Announcement • Nov 15
Edan Instruments, Inc. Focus on Medical Technology Advancement Shines At Medica 2023 Edan Instruments, Inc. showcased its innovative range of new products at MEDICA 2023 in Germany. This grand event, anticipated to draw over 81,000 visitors and host 4,500 exhibitors from around the globe, took place from November 13 to 16. Highlighting the new addition to its product lineup, EDAN introduced three gynecology products, showcasing its ongoing progress and reinforcing its status as a forefront technology leader in enhancing women's healthcare. Of noteworthy mention is the overseas debut of the Q andS Series handheld biofeedback and stimulation system, extending its current portfolio and adding valuable rehabilitation applications to its offerings, drawing significant interest from attendees. In the ultrasound section, two ready-to-launch products, the Nano Series handheld ultrasound systems and the Acclarix AX9, the portable diagnostics ultrasound system, convey freshness to the audiences. The designs combine portability and functionality, bringing in a user-friendly cutting-edge technology operation practice. The iV Series, EDAN's newly launched modular monitor, amazed the audiences with its innovative parameters, including the PresCCO continuous cardiac output, which gives doctors patients critical cardiac function parameters in real-time. The product has also been developed with high-standard parameters and clinical assistive applications for acute care. Caregivers can use authoritative tools to make decisions quickly in all ranges of acuity areas. The new telemetry systems, iT30 and iT50, which have attracted a lot of attention from clients, also met the audience on-site for the first time. For the laboratory sector, EDAN presents a full picture of its POCT&IVD innovations, including the i500, the ready-to-launch blood gas and chemistry analyzer, which provides all the benchtop features with a small footprint. In the veterinary field, EDAN's latest hematology product, H90X Vet, responds to the increasing demand for testing and has sparked keen interest among a larger number of veterinary departments and laboratories. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.068 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.051 (down from CN¥0.068 in 3Q 2022). Revenue: CN¥433.6m (up 13% from 3Q 2022). Net income: CN¥29.8m (down 24% from 3Q 2022). Profit margin: 6.9% (down from 10% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. New Risk • Oct 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 23
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.17 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥450.3m (down 3.8% from 2Q 2022). Net income: CN¥66.6m (down 34% from 2Q 2022). Profit margin: 15% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Jul 01
Edan Instruments, Inc. to Report First Half, 2023 Results on Aug 23, 2023 Edan Instruments, Inc. announced that they will report first half, 2023 results on Aug 23, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.085 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.24 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥639.7m (up 64% from 1Q 2022). Net income: CN¥140.4m (up 183% from 1Q 2022). Profit margin: 22% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥12.13, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 34x in the Medical Equipment industry in China. Total returns to shareholders of 82% over the past three years. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.11 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.068 (down from CN¥0.11 in 3Q 2021). Revenue: CN¥384.0m (up 2.9% from 3Q 2021). Net income: CN¥39.3m (down 40% from 3Q 2021). Profit margin: 10% (down from 18% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Announcement • Oct 20
Edan Instruments, Inc. Showcases Its First Molecular Diagnostics Analysis System, ClariLight CL30, at Medlab Asia & Asia Health 2022 EDAN Instruments, Inc. showcased its first molecular diagnostics analysis system, ClariLight CL30, at Medlab Asia & Asia Health 2022, announcing its start of a new segment in diagnostics applications. On this ASEAN region's leading exhibition, CL30 made its worldwide debut at Booth 6.D19, and a series of live demonstrations were held at IMPACT Exhibition Center, Bangkok, Thailand, Oct 19-21. The company showed its determination through a series of industrial layouts to face the challenge in the rapidly growing molecular diagnostic market, including previously acquiring the ClariLight molecular diagnostics point of care (POC) platform of LGC, a global life science tools leader from the United Kingdom. The new system is designed to offer effective solutions for infectious disease diagnostics by reducing the window period. Unlike PCR-based methods (generally non-portable, laboratory setting, time-consuming), CL30 produces molecular results as quick as 15 minutes, while multi-parameters cartridges and the extraction-free procedure allow massive and rapid molecular tests feasible. Respiratory infection control is an issue of global concern, and pathogen identification is important for identifying and containing potential outbreaks. The analytes(SARS-CoV-2, Influenza A/B, Influenza A/B & SARS-CoV-2, Influenza A/B & RSV) on CL30 are tailored to the typical respiratory infections. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥14.83, the stock trades at a trailing P/E ratio of 43.7x. Average trailing P/E is 32x in the Medical Equipment industry in China. Total returns to shareholders of 121% over the past three years. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥12.69, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 29x in the Medical Equipment industry in China. Total returns to shareholders of 96% over the past three years. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.10 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.17 (up from CN¥0.10 in 2Q 2021). Revenue: CN¥468.1m (up 24% from 2Q 2021). Net income: CN¥100.9m (up 67% from 2Q 2021). Profit margin: 22% (up from 16% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 27
Edan Instruments, Inc. Launches i20 EDAN Instruments, Inc. announced the official launch of the first-of-its-kind POC (Point-of-Care) fluorescence-based CO-OX blood gas and chemistry analysis system, i20, equipped with over 45 parameters, covering from blood gases, electrolyte, to CO-oximetry during the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (2022 AACC). EDAN held a series of live demonstrations of i20 in booth 1038 at McCormick Place Convention Center, Chicago, Jul. 26-28. The new system is designed to relieve the burden in selected patient care settings like intensive care units, pulmonary units, emergency departments, operating rooms, neonatal intensive care, etc. The technology and its photoluminescent biosensor increase the accuracy and stability sharply while eliminating the cost of maintenance, space, and staff training. The blood gas test is considered the most important POC test by many emergency-care providers. The newly added analytes (tHb, sO2, FO2Hb, FHHb, FCOHb, FMetHb) on i20, are tailored to the typical clinical applications of CO-oximetry, like poisoning or other clinical situations that alter Hb's ability to carry oxygen. Board Change • May 31
High number of new directors Independent Director Quanlu Zheng was the last director to join the board, commencing their role in 2022. Board Change • Apr 28
High number of new directors Independent Director Quanlu Zheng was the last director to join the board, commencing their role in 2022. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.085 (down from CN¥0.21 in 1Q 2021). Revenue: CN¥389.6m (down 24% from 1Q 2021). Net income: CN¥49.6m (down 60% from 1Q 2021). Profit margin: 13% (down from 25% in 1Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) also missed analyst estimates by 68%. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Edan Instruments, Inc. Announces Cash Dividend for the Year 2021, Payable on 29 April 2022 Edan Instruments, Inc. announced 2021 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 2.07000000. Record date is 28 April 2022Ex-date is 29 April 2022. Payment date is 29 April 2022. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥11.90, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 38x in the Medical Equipment industry in China. Total returns to shareholders of 107% over the past three years. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.28 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥373.2m (down 40% from 3Q 2020). Net income: CN¥65.8m (down 60% from 3Q 2020). Profit margin: 18% (down from 26% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.67 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥376.7m (down 59% from 2Q 2020). Net income: CN¥60.5m (down 85% from 2Q 2020). Profit margin: 16% (down from 43% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 27
First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.14 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥509.3m (up 42% from 1Q 2020). Net income: CN¥124.5m (up 53% from 1Q 2020). Profit margin: 25% (up from 23% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 15
Full year 2020 earnings released: EPS CN¥1.12 (vs CN¥0.23 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.32b (up 104% from FY 2019). Net income: CN¥653.2m (up 395% from FY 2019). Profit margin: 28% (up from 12% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 22
New 90-day high: CN¥19.94 The company is up 16% from its price of CN¥17.20 on 24 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 14% over the same period. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥17.36, the stock is trading at a trailing P/E ratio of 15.4x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 45x in the Medical Equipment industry in China. Total returns to shareholders over the past three years are 180%. Is New 90 Day High Low • Feb 04
New 90-day low: CN¥16.31 The company is down 15% from its price of CN¥19.12 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. Announcement • Jan 22
Edan Instruments, Inc. to Report Fiscal Year 2020 Results on Mar 15, 2021 Edan Instruments, Inc. announced that they will report fiscal year 2020 results on Mar 15, 2021 Is New 90 Day High Low • Jan 20
New 90-day low: CN¥16.65 The company is down 22% from its price of CN¥21.27 on 22 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: CN¥16.72 The company is down 17% from its price of CN¥20.04 on 10 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 06
New 90-day low: CN¥19.12 The company is down 17% from its price of CN¥23.10 on 07 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 4.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥654.9m, up 460% from the prior year. Total revenue was CN¥2.21b over the last 12 months, up 104% from the prior year. Announcement • Oct 20
Edan Instruments, Inc. to Report Q3, 2020 Results on Oct 27, 2020 Edan Instruments, Inc. announced that they will report Q3, 2020 results on Oct 27, 2020 Announcement • Jul 25
Edan Instruments, Inc. to Report First Half, 2020 Results on Aug 21, 2020 Edan Instruments, Inc. announced that they will report first half, 2020 results on Aug 21, 2020 
